Xinneng Medical has recently announced the successful closure of its Series A funding round, raising tens of millions of yuan. The round was spearheaded by Jiuxian Capital, with Diheng Investment also contributing, and Fu'an Capital acting as the exclusive financial advisor. The primary use of these funds will be to finalize product development and conduct research on the self-powered leadless cardiac pacemaker. Additionally, the investment will facilitate the expansion of the self-generating technology platform into other areas of implantable medical devices.

Established in September 2024, Xinneng Medical is a joint venture co-founded by Professor Li Zhou, who holds positions at both the School of Biomedical Engineering at Tsinghua University and Beijing Tsinghua Changgung Hospital, along with a team from Fuwai Hospital, Chinese Academy of Medical Sciences. The company's pioneering self-generating technology is a world-first, harnessing energy from heartbeats. This innovation is anticipated to substantially prolong the lifespan of leadless pacemakers, potentially allowing for a single implantation to last a lifetime.

At present, the team has successfully developed several core technologies related to this field and has accumulated a wealth of R&D achievements, supported by validations from animal experiments. The domestic pacemaker market currently suffers from low penetration and inadequate localization, with leadless pacemakers emerging as a rapidly growing segment. However, the existing products are constrained by battery limitations, leading to short lifespans. The global market is predominantly controlled by foreign brands, and to date, no domestically produced leadless pacemaker has received approval in China.

Xinneng Medical's self-powered solution is unique on a global scale, addressing the fundamental issue of energy supply in a distinctive manner. The company's core team comprises scientists, clinical experts, and industry leaders. By leveraging its foundational technology platform, Xinneng Medical can explore multiple avenues within the realm of implantable medical devices, presenting vast opportunities for a platform-based strategy. The investors in this round have all acknowledged the rarity of its original self-powered technology and the significant value of its platform.